Richmond Pharmacology is excited to join the ASGCT Annual Meeting 2026 in Boston, Massachusetts, USA, on 12–15 May 2026.

As one of the world’s premier events in gene and cell therapy, the ASGCT Annual Meeting brings together scientists, clinicians, regulatory experts, and industry innovators to explore ground breaking advances in genetic medicine and the translation of new technologies into safe, effective therapies.

Representing Richmond Pharmacology:

  • Dr Jörg Taubel, Chief Executive Officer
  • Stephen Wilkinson, Business Development Manager

Our Focus at the Meeting

  • Advances in gene and cell therapy platforms
  • Translational pathways to early‑phase and first‑in‑human studies
  • Safety, regulatory, and ethical considerations in genetic medicine
  • Biomarker‑driven and mechanistic insights for clinical trial design
  • Cross‑sector collaboration between academia, biotech, and industry sponsors

Connect With Us

If you are attending the ASGCT Annual Meeting 2026 and would like to explore collaboration or development opportunities:

📧 fasteranswers@richmondpharmacology.com

Find out more here: Annual Meeting | ASGCT Annual Meeting

Latest news

Richmond Pharmacology Appoints John Hotti as Chief Technology Officer

April 22, 2026
Richmond Pharmacology is pleased to announce the appointment of John Hotti as Chief Technology Officer (CTO), strengthening the company’s leadership in technology-enabled clinical research.
Read more

Events

Clinical Trials Innovation Programme

10 - 11 February 2026
Richmond Pharmacology is pleased to attend the Clinical Trials Innovation Programme Conference in Nice, France, 10–11 February 2026.
View event